Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Biosimulation Software for Evaluating Regulatory Submissions PRINCETON, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its...

Certara to Participate in the William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, Chief Executive Officer, and Andrew Schemick,...

Certara Releases New Versions of Its Preeminent Quantitative Systems Pharmacology (QSP) Simulators for Expediting Development of Biologics and Immuno-oncology Therapies PRINCETON, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of new versions of its Immunogenicity (IG) and...

Certara Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Guidance PRINCETON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2021. ...